DOUBLES cure rate for patients with high risk prostate cancer,
as compared to conventional external beam radiation therapy alone.
1 According to the largest international study of 1597 patients receiving Pd-103 implants across the world. Tang, Outcomes after PD-103 versus I-125 for low dose rate prostate brachytherapy monotherapy: An international, multi-institutional study, Radiotherapy & Oncology 2023
2 According to the ASCENDE-RT trial (Morris, International Journal of Radiation Oncology, Biology, and Physics, 2017), brachytherapy boost increased the biochemical progression-free-survival rates from 62% at 9 years to 83% at 9 years. More modern studies using intraoperative planning techniques, such as the TRIP randomized trial in Japan (presented in 2023), show a 9-year progression-free-survival rate of 90% for patients with high risk prostate cancer who receive a brachytherapy boost.